Carlsmed closed an oversubscribed $30 million Series B funding round, The company plans to use proceeds to ramp commercialization of aprevo®, Carlsmed’s FDA-cleared personalized surgical devices.
In 2020, the company closed a $10 million Series A financing to commercialize a digital + surgical planning solution and personalized aprevo implants for the correction of spinal deformity.
“Traditionally, patients undergoing spinal surgery are at risk for postoperative complications and revision surgery. Our goal is for aprevo® to be the last spinal surgery a patient will ever need,” said Mike Cordonnier, CEO of Carlsmed. “Unlike conventional implants that are mass produced in stock shapes and sizes, each aprevo® device is designed for a specific patient, with spinal alignment correction built into the device.”
Carlsmed closed an oversubscribed $30 million Series B funding round, The company plans to use proceeds to ramp commercialization of aprevo®, Carlsmed’s FDA-cleared personalized surgical devices.
In 2020, the company closed a $10 million Series A financing to commercialize a digital + surgical planning solution and personalized aprevo...
Carlsmed closed an oversubscribed $30 million Series B funding round, The company plans to use proceeds to ramp commercialization of aprevo®, Carlsmed’s FDA-cleared personalized surgical devices.
In 2020, the company closed a $10 million Series A financing to commercialize a digital + surgical planning solution and personalized aprevo implants for the correction of spinal deformity.
“Traditionally, patients undergoing spinal surgery are at risk for postoperative complications and revision surgery. Our goal is for aprevo® to be the last spinal surgery a patient will ever need,” said Mike Cordonnier, CEO of Carlsmed. “Unlike conventional implants that are mass produced in stock shapes and sizes, each aprevo® device is designed for a specific patient, with spinal alignment correction built into the device.”
Copy to clipboard 
